<DOC>
	<DOCNO>NCT02526550</DOCNO>
	<brief_summary>This study undertaken ass immunogenicity safety booster dose live attenuate chimeric Japanese Encephalitis vaccine ( JE-CV ) primary vaccination SA14-14-2 Thai child age 1 &lt; 5 year . In addition , assess impact duration interval primary vaccination subsequent booster response .</brief_summary>
	<brief_title>Immunogenicity Live Attenuated Chimeric JE Vaccine ( IMOJEV ) Booster Dose Thai Children Primed With CD.JEVAX</brief_title>
	<detailed_description>The subject receive one booster dose IMOJEV hepatitis A vaccine ( inactivated vaccine GlaxoSmithKline ) concomitant vaccine . Blood sample collect assess Japanese Encephalitis Neutralizing Antibody baseline ( pre-vaccination ) 4 week post -vaccination .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children age 1 &lt; 5 year day inclusion History receive 1 dose CD.JEVAX 915 month prior enrollment In good general health time inclusion Provision inform consent parent ( ) legal guardian ( ) Receipt blood blood product past 3 month Acute febrile illness day vaccination ( Body Temperature ≥ 38 ◦C ) Previous receipt 2 dos vaccine JE virus Known hypersensitivity vaccine components Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Planned receipt live attenuate vaccine within 4 week follow trial vaccination</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Live attenuate Japanese Encephalitis vaccine</keyword>
	<keyword>IMOJEV</keyword>
	<keyword>CD.JEVAX</keyword>
	<keyword>Booster</keyword>
	<keyword>Thai child</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Interchangeability</keyword>
	<keyword>Hepatitis A vaccine</keyword>
	<keyword>Vaccination Other Immunization Procedure</keyword>
</DOC>